Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with lewy bodies, Parkinson's disease, and Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 38, Issue 1, 2014, Pages 63-73

  Kaerst, Lisa ^a   Kuhlmann, Andre ^a   Wedekind, Dirk ^a   Stoeck, Katharina ^a   Lange, Peter ^a   Zerr, Inga ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Alzheimer's disease; amyloid ; cerebrospinal fluid; clinical diagnosis; dementia; dementia with Lewy bodies; Parkinson's disease; tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD CHEMISTRY; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ALZHEIMER'S DISEASE; AMYLOID-Β; CEREBROSPINAL FLUID; CLINICAL DIAGNOSIS; DEMENTIA; DEMENTIA WITH LEWY BODIES; PARKINSON'S DISEASE; TAU;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; PARKINSON DISEASE; PEPTIDE FRAGMENTS; RETROSPECTIVE STUDIES; TAU PROTEINS;

EID: 84887223575     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130995     Document Type: Article

References (41)

1. Weisman D, McKeith I (2007) Dementia with Lewy bodies. Semin Neurol 27, 42-47. (Pubitemid 46239038)
2. Barber R, Panikkar A, McKeith IG (2001) Dementia with Lewy bodies: Diagnosis and management. Int J Geriatr Psychiatry 16 (Suppl 1), S12-S18. (Pubitemid 33741564)
3. Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC, Thal LJ, Corey-Bloom J (2006) What best differentiates Lewy body from Alzheimer's disease inearly-stage dementia? Brain 129, 729-735. (Pubitemid 43278234)
4. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson D, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith IG, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B (2007) Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 22, 1689-1707. (Pubitemid 47597592)
5. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 47, 1113-1124. (Pubitemid 26374873)
6. Morris JC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43, 2412-2414. (Pubitemid 23346995)
7. Gloeckner SF, Meyne F, Wagner F, Heinemann U, Krasni-anski A, Meissner B, Zerr I (2008) Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. J Alzheimers Dis 14, 17-25. (Pubitemid 352039015)
8. Meyne F, Gloeckner SF, Ciesielczyk B, Heinemann U, Kras-nianski A, Meissner B, Zerr I (2009) Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders. J Alzheimers Dis 17, 863-873.
9. Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, Nishizawa M, Ikeuchi T (2010) Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry 81, 608-610.
10. Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hul-staert F (2001) CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewybodies. Phospho-Tau International Study Group. Neurol Sci 22, 77-78. (Pubitemid 33622091)
11. Henneman WJ, Vrenken H, Barnes J, Sluimer IC, Verwey NA, Blankenstein MA, Klein M, Fox NC, Scheltens P, Barkhof F, van der Flier WM (2009) Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology 73, 935-940.
12. Vanderstichele H, de Vreese K, Blennow K, Andreasen N, Sindic C, Ivanoiu A, Hampel H, Bürger K, Parnetti L, Lanari A, Padovani A, DiLuca M, Bläser M, Olsson AO, Pottel H, Hulstaert F, Vanmechelen E (2006) Analytical performance and clinical utility of the INNOTEST PHOSPHO-Tau181P assay for discrimination between Alzheimer's disease and dementia with Lewy body. Clin Chem Lab Med 44, 1472-1480. (Pubitemid 44967698)
13. Compta Y, Marti MJ, Ibarretxe-Bilbao N, Junque C, Vallde-oriola F, Munoz E, Ezquerra M, Rios J, Tolosa E (2009) Cerebrospinal tau, phospho-tau, and beta-amyloid and neu-ropsychological functions in Parkinson's disease. Mov Disord 24, 2203-2210.
14. Spies PE, Slats D, Sjögren JM, Kremer BP, Verhey FR, Rikkert MG, Verbeek MM (2010) The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia. Curr Alzheimer Res 7, 470-476.
15. Aerts MB, Esselink RA, Claassen JA, Abdo WF, Bloem BR, Verbeek MM (2011) CSF tau, Abeta42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease. J Alzheimers Dis 27, 377-384.
16. Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki HW, Sparbier K, Smirnov A, Cepek L, Trenkwalder C, Ruther E, Kornhuber J, Otto M, Wiltfang J (2006) CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 129, 1177-1187.
17. Samuel W, Caligiuri M, Galasko D, Lacro J, Marini M, McClure FS, Warren K, Jeste DV (2000) Better cognitive and psychopathologic response to donepezil in patients prospec-tively diagnosedasdementia withLewy bodies:Apreliminary study. Int J Geriatr Psychiatry 15, 794-802.
18. McKeith IG, Ballard CG, Perry RH, Ince PG, O'Brien JT, Neill D, Lowery K, Jaros E, Barber R, Thompson P, Swann A, Fairbairn AF, Perry EK (2000) Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 54, 1050-1058. (Pubitemid 30151844)
19. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R (2004) Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 351, 2509-2518. (Pubitemid 39603164)
20. Harding AJ, Broe GA, Halliday GM (2002) Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 125, 391-403. (Pubitemid 34127441)
21. Henriksen AL, St Dennis C, Setter SM, Tran JT (2006) Dementia with lewy bodies: Therapeutic opportunities and pitfalls. Consult Pharm 21, 563-575. (Pubitemid 44543624)
22. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 65, 1863-1872. (Pubitemid 43970103)
23. Beach TG, Monsell SE, Phillips LE, Kukull W (2012) Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 71, 266-273.
24. Alladi S, Xuereb J, Bak T, Nestor P, Knibb J, Patterson K, Hodges JR (2007) Focal cortical presentations of Alzheimer's disease. Brain 130, 2636-2645. (Pubitemid 47511719)
25. Fujishiro H, J, Boeve FT, Smith BF, Graff-Radford GE, Wszolek UR, Knopman ZK, DS (2008) Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases. J Neu-ropathol Exp Neurol 67, 649-656.
26. Geschwind MD, Shu H, Haman A, Sejvar JJ, Miller BL (2008) Rapidly progressive dementia. Ann Neurol 64, 97-108.
27. Stoeck K, Sanchez-Juan P, Gawinecka J, Green A, Ladogana A, Pocchiari M, Sanchez-Valle R, Mitrova E, Sklaviadis T, Kulczycki J, Slivarichova D, Saiz A, Calero M, Knight R, Aguzzi A, Laplanche JL, Peoc'h K, Schelzke g, Karch A, van Duijn CM, Zerr I (2012) Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: A longitudinal multicentre study over 10 years. Brain 135, 3051-3061.
28. Querfurth HW, LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362, 329-344.
29. Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O (2010) Evaluation of CSF biomarkers as predictors of Alzheimer's disease: A clinical follow-up study of 4. 7 years. J Alzheimers Dis 21, 1119-1128.
30. Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM (2009) Cerebrospinal fluid biomarkers and rateofcognitive declineinvery mild dementia of the Alzheimer type. Arch Neurol 66, 638-645.
31. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttila T, Wallin A, Jonhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385-393.
32. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Tro-janowski JQ, Initiative AsDN (2009) Cerebrospinal fluid biomarker signatureinAlzheimer's disease neuroimaging initiative subjects. Ann Neurol 65, 403-413.
33. Formichi P, Battisti C, Radi E, Federico A (2006) Cere-brospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. J Cell Physiol 208, 39-46. (Pubitemid 43848987)
34. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM (2003) Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289, 2094-2103. (Pubitemid 37430211)
35. Mollenhauer B, Esselmann H, Trenkwalder C, Schulz-Schaeffer W, Kretzschmar H, Otto M, Wiltfang J, Bibl M (2011) CSF amyloid-beta peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's Disease. J Alzheimers Dis 24, 383-391.
36. Wada-Isoe K, Kitayama M, Nakaso K, Nakashima K (2007) Diagnostic marker for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study. J Neurol Sci 260, 33-37. (Pubitemid 47212190)
37. Simic G, Boban M, Sarac H, Grbic K, Hof PR, Hamann C, Ackl N, Bader B, Danek A. (2008) CSF tau proteins in evaluation of patients with suspected dementia. New Trends in Alzheimer and Parkinson Related Disorders: ADPD 2007, Hanin I, Windisch M, Poewe W, Fisher A, eds. Medimond, Bologna, pp. 239-243.
38. Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D'Amore C, Pierguidi L, Tambasco N, Rossi A, Calabresi P (2008) Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry 64, 850-855.
39. Prikrylova Vranova H, Mares J, Hlustik P, Nevrly M, Ste-jskal D, Zapletalova J, Obereigneru R, Kanovsky P (2012) Tau protein and beta-amyloid (1-42) CSF levels in different phenotypes of Parkinson's disease. J Neural Transm 119, 353-362.
40. Jellinger KA (2011) CSF biomarkers in different phenotypes of Parkinson disease. J Neural Transm 119, 455-456.
41. Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C, Schulte C, Leyhe T, Keller S, Melms A, Gasser T, Berg D (2009) Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 34, 107-112.